Therapeutic drug monitoring in child and adolescent psychiatry

Pharmacopsychiatry

Volumn 44, Issue 6, 2011, Pages 249-253

  Egberts, K M ^a   Mehler Wex, C ^b   Gerlach, M ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

child and adolescent psychiatry; developmental psychopharmacology; psychopharmacotherapy; therapeutic drug monitoring

Indexed keywords

ARIPIPRAZOLE; ATOMOXETINE; CLOZAPINE; FLUOXETINE; FLUVOXAMINE; METHYLPHENIDATE; OLANZAPINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SERTRALINE; ZIPRASIDONE;

ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; BODY MASS; CELL MIGRATION; CHILD PSYCHIATRY; DEPRESSION; DRUG ABSORPTION; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HUMAN; LIVER METABOLISM; MENTAL PATIENT; NERVE CELL DIFFERENTIATION; OBSESSIVE COMPULSIVE DISORDER; OFF LABEL DRUG USE; PHARMACOGENETICS; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOSIS; REVIEW; SCHIZOPHRENIA;

ADOLESCENT; ADOLESCENT PSYCHIATRY; CHILD; DRUG MONITORING; HUMANS; MENTAL DISORDERS; PSYCHOPHARMACOLOGY; PSYCHOTROPIC DRUGS;

EID: 80053386252     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0031-1286291     Document Type: Review

References (31)

1. Aichhorn W, Marksteiner J, Walch T et al. Age and Gender Effects on Olanzapine and Risperidone Plasma Concentrations in Children and Adolescents. J Child Adolesc Psychopharmacol: 2007; 17 665 673 (Pubitemid 350058974)
2. Bachmann C, Haberhausen M, Heinzel-Gutenbrunner M et al. Large intraindividual variability of Olanzapine serum concentrations in adolescent patients. Ther Drug Monit: 2008; 30 108 112 (Pubitemid 351161108)
3. Bachmann C, Rieger-Gies A, Heinzel-Gutenbrunner M. Large variability of aripiprazole and hydroaripiprzole serum concentrations in adolescent patients with schizophrenia. Ther Drug Monit: 2008; 30 462 466
4. Baumann P, Hiemke C. Ulrich et al. The AGNP-TDM expert group consensus guidelines: Therapeutic drug monitoring in Psychiatry. Pharmacopsychiatry: 2004; 37 243 65 (Pubitemid 39587052)
5. Child and Adolescent Psychiatry Trials Network [ www.captn.org ]
6. Correll C U, Manu P, Olshanskiy V et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA: 2009; 28 1765 1773 Erratum in: JAMA 2009; 302: 2322
7. Findling R, Reed M, Myers C et al. Paroxetine Pharmacokinetics in depressed chidren and adolescents. J Am Acad Child Adolesc Psychiatry: 1999; 38 952 959 (Pubitemid 29353029)
8. Fleischhaker C, Heiser P, Hennighausen K et al. Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone. J Neural Transm: 2008; 115 1599 1608
9. Gerlach M, Hnnerkopf R, Rothenhfer S et al. Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders. Pharmacopsychiatry: 2007; 40 72 76 (Pubitemid 46697678)
10. Gerlach M, Klampfl K, Mehler-Wex C et al. Besonderheiten in der Therapie mit Neuro- Psychopharmaka im Kindes- und Jugendalter. In Gerlach M, Mehler-Wex C, Walitza S, Warnke A, Wewetzer C. editors. Neuro- Psychopharmaka im Kindes- und Jugendalter. Grundlagen und Therapie. Wien, New York Springer-Verlag: 2009; 73 89
11. Gerlach M, Klampfl K, Warnke A et al. Besonderheiten der Therapie mit Neuro-Psychopharmaka im Kindes- und Jugendalter, Arzneimitteltherapie psychischer und neurologischer Erkrankungen. Psychopharmakotherapie: 2010; 17 118 125
12. Gerlach M, Rothenhfer S, Mehler-Wex C et al. Therapeutisches Drug-Monitoring in der Kinder- und Jugendpsychiatrie Grundlagen und praktische Empfehlungen. Z Kinder-Jugendpsychiatr: 2006; 34 5 13 (Pubitemid 43155921)
13. Gerlach M, Schulz E, Fegert J M. Editorial Therapeutisches Drug-Monitoring, eine Strategie zur Verbesserung der Arzneimittelsicherheit in der Kinder- und Jugendpsychiatrie und Psychotherapie. Z Kinder-Jugendpsychiatr: 2005; 33 157 158 (Pubitemid 41103559)
14. Gerlach M, Warnke A. Allgemeine Aspekte und Besonderheiten der Neuropsychopharmakologie im Kindes- und Jugendalter. In Gerlach M, Warnke A, Wewetzer C. editors. Neuro-Psychopharmaka im Kindes- und Jugendalter. Grundlagen und Therapie. Wien Springer: 2004; 51 60
15. Gerlach M, Wewetzer C. Entwicklungspsychopharmakologie. In Herpertz-Dahlmann B, Resch F, Schulte-Markwort M, Warnke A. editors. Entwicklungspsychiatrie. Biopsychologische Grundlagen und die Entwicklung psychischer Strungen. 2. vollstndig berarbeitete und erweiterte Auflage. Stuttgart Schattauer: 2008; 372 407
16. Giedd N, Blumenthal J, Jeffries N O et al. Brain development during childhood and adolescence: a longitudinal MRI study. Nature Neuroscience: 1999; 2 861 863 (Pubitemid 30602596)
17. Hiemke C, Baumann P, Laux G et al. Therapeutisches Drug Monitoring in der Psychiatrie. Konsensus-Leitlinie der AGNP. Psychopharmakotherapie: 2005; 12 166 182 (Pubitemid 41558514)
18. Klampfl K, Mehler-Wex C, Warnke A et al. Therapeutisches Drug- Monitoring in der Kinder- und Jugendpsychiatrie. Psychopharmakotherapie: 2010; 17 193 200
19. Klampfl K, Taurines R, Preuss A et al. Serum concentrations, therapeutic response and side effects in children and adolescents with impulsive-aggressive symptoms during risperidone therapy. Pharmacopsychiatry: 2010; 43 58 65
20. March J, Karayal O, Chrisman A. CAPTN: The Paediatric Adverse Event Rating Scale. In Novins D K. DeYoung. editors. The Scientific Proceedings of the 2007 Annual Meeting of the American Academy of Child and Adolescent Psychiatr. Boston: 2007
21. Meesters R J, van Kampen J J, Reedijk M L et al. Ultrafast and high-throughput mass spectrometric assay for therapeutic drug monitoring of antiretroviral drugs in pediatric HIV-1 infection applying dried blood spots. Anal Bioanal Chem: 2010; 398 319 328
22. Mehler-Wex C, Klch M, Kirchheiner J et al. Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy. Child Adolesc Psychiatry Ment Health: 2009; 3 14 10.1186/1753-200-3-14
23. Pichini S, Papaseit E, Joya X et al. Pharmacokinetics and therapeutic drug monitoring of psychotropic drugs in pediatrics. Ther Drug Monit: 2009; 31 283 318
24. Poznanski E O, Mokros H B. Childrens depression rating scale, revised (CDRS-R). Los Angeles Western Psychological Services: 1996
25. Rapp P R, Bachevalier J. Cognitive development and aging. In Squire L R, Bloom F E, McConnell S K, Roberts J L, Spitzer N C, Zigmond M. editors. Fundamental Neuroscience. London Academic Press: 2003; 1167 1200
26. Reis M, Olsson G, Carlsson B et al. Serum Levels of Citalopram and its main metabolites in adolescent patients treated in a naturalistic clinical setting. J Clinical Psychopharmacol: 2002; 22 406 413 (Pubitemid 34810331)
27. Safer D J, Zito J M. Treatment-Emergent Adverse Events from Selective Serotonin Reuptake Inhibitors by Age Group: Children versus Adolescents. Journal of Child and Adolescent Psychopharmacology: 2006; 16 159 169
28. Seeman P, Bzowej N H, Guan H-C et al. Human brain dopamine receptors in children and aging adults. Synapse: 1987; 1 399 404
29. Smink B E, Hofman B J, Dijkhuizen A et al. The concentration of oxazepam and oxazepam glucuronide in oral fluid, blood and serum after controlled administration of 15 and 30mg oxazepam. Br J Clin Pharmacol: 2008; 66 556 560
30. van Riet-Nales D A, Schobben A F, Egberts T C et al. Effects of the pharmaceutical technologic aspects of oral pediatric drugs on patient-related outcomes: a systematic literature review. Clin Ther: 2010; 32 924 938
31. Vitiello B. Research in child and adolescent psychopharmacology: recent accomplishments and new challenges. Psychopharmacology: 2007; 191 5 13 (Pubitemid 46294940)